Interaksi Tobramisin

TOBI Podhaler should not be administered concomitantly with ethacrynic acid, furosemide, urea, or intravenous mannitol. (label Tobramisin, Interaksi obat)

Drug Interactions Drugs with Ototoxic Potential (see WARNINGS ) Especially in the presence of impaired renal function, the use of parenterally administered bumetanide in patients to whom aminoglycoside antibiotics are also being given should be avoided, except in life-threatening conditions. (label Bumetanid, Interaksi obat)

In vitro mixing of penicillins and aminoglycosides should be avoided during concomitant therapy and the drugs should be administered separately. (label Dikloksasilin, Interaksi obat)

Because of foscarnet's tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B, cyclosporine, acyclovir, methotrexate, tacrolimus and intravenous pentamidine (see above) unless the potential benefits outweigh the risks to the patient. (label Foskarnet, Interaksi obat)

TOBI Podhaler should not be administered concomitantly with ethacrynic acid, furosemide, urea, or intravenous mannitol. (label Tobramisin, Interaksi obat)

Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as cisplatin, cephaloridine, kanamycin, amikacin, neomycin, polymyxin B, colistin, paromomycin, streptomycin, tobramycin, vancomycin, and viomycin, should be avoided (see PRECAUTIONS, Drug Interactions section). (label Gentamisin, Peringatan kotak hitam)

Aminoglycosides : Avoid concomitant use with aminoglycosides. (label Karboplatin, Interaksi obat)

Concurrent and/or sequential systemic, oral or topical use of other aminoglycosides, including paromomycin and other potentially nephrotoxic and/or neurotoxic drugs such as bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin, should be avoided because the toxicity may be additive. (label Neomisin, Peringatan kotak hitam)

Because the nephrotoxic effects may be additive, the concomitant or sequential use of Pentamidine Isethionate and other nephrotoxic drugs such as aminoglycosides, amphotericin B, cisplatin, foscarnet, or vancomycin should be closely monitored and avoided, if possible. (label Pentamidin, Interaksi obat)

THE CONCURRENT OR SEQUENTIAL USE OF OTHER NEUROTOXIC AND/OR NEPHROTOXIC DRUGS WITH POLYMYXIN B SULFATE, PARTICULARLY BACITRACIN, STREPTOMYCIN, NEOMYCIN, KANAMYCIN, GENTAMICIN, TOBRAMYCIN, AMIKACIN, CEPHALORIDINE, PAROMOMYCIN, VIOMYCIN, AND COLISTIN SHOULD BE AVOIDED. (label Polimiksin B, Peringatan kotak hitam)

Avoid concomitant use of torsemide and aminoglycoside antibiotics, if possible. (label Torasemid, Interaksi obat)

However, this is of special importance in patients at risk of or having underlying renal dysfunction and patients taking concomitant nephrotoxic agents such as cyclosporine, tacrolimus, aminoglycosides, vancomycin and non-steroidal anti-inflammatory drugs [See Adverse Reactions (6.2) and Clinical Pharmacology (12.3) ]. (label Adefovir, Peringatan dan perhatian)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (label Tobramisin, Interaksi obat)

• Aminoglycosides: May lower serum calcium for prolonged periods ( 7.1 ) (label Asam zoledronat, Interaksi obat)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (label Tobramisin, Interaksi obat)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (label Tobramisin, Interaksi obat)

Drug Interactions Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine. (label Atrakurium, Interaksi obat)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (label Tobramisin, Interaksi obat)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (label Tobramisin, Interaksi obat)

Some examples include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ] . (label Efavirenz, lamivudin, dan tenofovir, Interaksi obat)

Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ] . (label Elvitegravir, kobisistat, emtrisitabin, dan tenofovir, Interaksi obat)

Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ] . (label Emtrisitabin dan tenofovir, Interaksi obat)

Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, adefovir dipivoxil, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.5) ] . (label Emtrisitabin, rilpivirin, dan tenofovir, Interaksi obat)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (label Tobramisin, Interaksi obat)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (label Tobramisin, Interaksi obat)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (label Tobramisin, Interaksi obat)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (label Tobramisin, Interaksi obat)

Aminoglycosides or other agents that interfere with neuromuscular transmission may potentiate the effect of XEOMIN; co-administer only with caution and close observation ( 7 ) (label IncobotulinumtoxinA, Interaksi obat)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (label Tobramisin, Interaksi obat)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (label Tobramisin, Interaksi obat)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (label Tobramisin, Interaksi obat)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (label Tobramisin, Interaksi obat)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (label Tobramisin, Interaksi obat)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (label Tobramisin, Interaksi obat)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (label Tobramisin, Interaksi obat)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (label Tobramisin, Interaksi obat)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (label Tobramisin, Interaksi obat)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (label Tobramisin, Interaksi obat)

Examples Cyclosporine A, trimethoprim/sulfamethoxazole, bile acid sequestrants (cholestyramine), rifampin as well as aminoglycoside, cephalosporin, fluoroquinolone and penicillin classes of antimicrobials Drugs Modulating Glucuronidation Clinical Impact Concomitant use with drugs inducing glucuronidation decreases MPA systemic exposure, potentially reducing mycophenolate… (label Mikofenolat, Interaksi obat)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (label Tobramisin, Interaksi obat)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (label Tobramisin, Interaksi obat)

Patients receiving concomitant treatment of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like agents), or muscle relaxants, should be observed closely because the effect of BOTOX may be potentiated ( 7.1 , 7.4 ) (label OnabotulinumtoxinA, Interaksi obat)

Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (label Piperasilin dan tazobaktam, Interaksi obat)

Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as Rocuronium Bromide Injection include certain antibiotics (e.g., aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). (label Rokuronium, Interaksi obat)

Aminoglycosides: Increased potential of nephrotoxicity and ototoxicity. (label Sefepim, Interaksi obat)

Aminoglycosides: Increased potential of nephrotoxicity. (label Sefoksitin, Interaksi obat)

Drug Interactions As with other cephalosporins, cefotaxime may potentiate the nephrotoxic effects of nephrotoxic drugs such as aminoglycosides, NSAIDs and furosemide. (label Sefotaksim, Interaksi obat)

If CEFOTAN® and an aminoglycoside are used concomitantly, renal function should be carefully monitored, because nephrotoxicity may be potentiated. (label Sefotetan, Perhatian)

Drug Interactions Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporin antibiotics. (label Sefprozil, Interaksi obat)

Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (label Seftazidim, Interaksi obat)

Vancomycin, Amsacrine, Aminoglycosides, and Fluconazole Vancomycin, amsacrine, aminoglycosides, and fluconazole are physically incompatible with ceftriaxone in admixtures [see Dosage and Administration (2.3) ]. (label Seftriakson, Interaksi obat)

The safety of cidofovir injection has not been evaluated in patients receiving other known potentially nephrotoxic agents, such as intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents (see DOSAGE AND ADMINISTRATION ). (label Sidofovir, Peringatan)

…ciprofloxacin melphalan amphotericin B azapropazon cimetidine tacrolimus fibric acid derivatives (e.g., bezafibrate, fenofibrate) gentamicin ketoconazole colchicine ranitidine methotrexate tobramycin diclofenac trimethoprim with sulfamethoxazole naproxen vancomycin sulindac During the concomitant use of a drug that may exhibit additive or synergistic renal impairment… (label Siklosporin, Interaksi obat)

Caution should be exercised when using agents (e.g., aminoglycosides and amphotericin B) that are known to have a deleterious effect on renal function. (label Sirolimus, Peringatan dan perhatian)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (label Tobramisin, Interaksi obat)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (label Tobramisin, Interaksi obat)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (label Takrolimus, Peringatan dan perhatian)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (label Tobramisin, Interaksi obat)

Some examples include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.2) ]. (label Tenofovir, Interaksi obat)

Aminoglycosides or other agents interfering with neuromuscular transmission Anticholinergic drugs Botulinum neurotoxin products Muscle relaxants Aminoglycoside antibiotics, anticholinergic agents, or any other agents that interfere with neuromuscular transmission may potentiate the effect of DAXXIFY; co-administer only with caution and close observation. (label Toksin botulinum tipe A, Interaksi obat)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (label Tobramisin, Interaksi obat)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (label Tobramisin, Interaksi obat)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (label Tobramisin, Interaksi obat)

The risk is higher in older patients, patients who are receiving higher doses, who have an underlying hearing loss, who are receiving concomitant therapy with another ototoxic agent, such as an aminoglycoside or who have underlying renal impairment. (label Vankomisin, Peringatan dan perhatian)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

UNASYN and aminoglycosides should not be reconstituted together due to the in vitro inactivation of aminoglycosides by the ampicillin component of UNASYN. (label Ampisilin dan sulbaktam, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

Closely evaluate the renal function of patients Examples: Aminoglycosides, amphotericin B, systemic bacitracin, cisplatin, cyclosporine, foscarnet, or parenteral vancomycin Angiotensin Converting Enzyme (ACE) Inhibitors Clinical Impact: The hyponatremic and hypotensive effects of ACE inhibitors may be diminished by the concomitant administration of aspirin due… (label Butalbital, aspirin, kafein, dan kodein, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

Drug Interactions Certain other antibiotics (aminoglycosides and polymyxin) have also been reported to interfere with the nerve transmission at the neuromuscular junction. (label Kolistimetat, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

Aminoglycoside antibiotics, local and some general anesthetics, antiarrhythmic agents, and other drugs that interfere with neuromuscular transmission should be used cautiously, if at all. (label Piridostigmin, Interaksi obat)

Before therapy with ZEMDRI is instituted, careful inquiry about previous hypersensitivity reactions to other aminoglycosides should be made. (label Plazomisin, Peringatan dan perhatian)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

The following antibiotics have been associated with various degrees of paralysis: aminoglycosides (such as neomycin, streptomycin, kanamycin, gentamicin, and dihydrostreptomycin); tetracyclines; bacitracin; polymyxin B; colistin; and sodium colistimethate. (label Vekuronium, Perhatian)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

…assess the need for additional doses of Cisatracurium Besylate Injection, and to determine whether adjustments need to be made to the dose with subsequent administration. † Examples: aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, sodium colistimethate Drug or Drug Class Clinical Implications * Succinylcholine The use of… (label Sisatrakurium, Interaksi obat)